April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
PARP Inhibitor Benefit in Ovarian Cancer Unaffected by BRCA Status
March 14th 2017Results of a recent phase III trial suggested that the PARP inhibitor niraparib warrants consideration for patients with recurrent, platinum-sensitive, high-grade ovarian cancer, irrespective of <em>BRCA</em> status, a reviewer of the study concluded.
Read More
Readmission Rates Misleading in Ovarian Cancer
March 14th 2017Patients with ovarian cancer who were treated at the highest volume centers had superior overall survival but also higher readmission rates compared with lower volume hospitals, casting doubt on the value of this measure for patients with cancer.
Read More
Expert Explains the Importance of Genetic Testing for Patients With Ovarian Cancer
March 14th 2017During the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland, Jubilee Brown, MD, offered advice on where to access this counseling and why it is so important for women with ovarian cancer to advocate for genetic testing.
Read More
Rucaparib Promising Agent for Patients With Relapsed Ovarian Cancer
March 14th 2017Patients with relapsed, platinum-sensitive, high-grade, ovarian cancer saw activity with the PARP inhibitor rucaparib, according to findings from the ARIEL2 study presented at the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland.
Read More
Tumor Gene Methylation May Predict Ovarian Cancer Response to PARP Inhibitor
March 13th 2017Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib, according to a subgroup analysis of the randomized ARIEL2 trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Read More
Ideal IP Chemo Approach in Ovarian Cancer Remains to be Seen
February 17th 2017The much anticipated initial results of the Gynecologic Oncology Group 252 trial failed to provide additional clarity for the use of intravenous versus intraperitoneal chemotherapy in patients with ovarian cancer.
Read More
Niraparib Receives Priority Review Designation from FDA for Ovarian Cancer
December 20th 2016A new drug application (NDA) for niraparib has been granted priority review by the FDA for use as a maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to platinum-based chemotherapy, according to Tesaro, the manufacturer of the PARP 1/2 inhibitor.
Read More
Current and Emerging Roles of PARP Inhibition in Ovarian Cancer
December 8th 2016Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses the current and emerging roles of PARP inhibition in ovarian cancer.
Watch
Bevacizumab Receives FDA Approval for Platinum-Sensitive Ovarian Cancer
December 7th 2016The FDA has expanded the approval for bevacizumab (Avastin) in ovarian cancer to include patients with platinum-sensitive recurrent disease as part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to Genentech, which developed the drug.
Read More
Effects of Stress on Ovarian Cancer, Other Cancer Types
November 16th 2016Susan Lutgendorf, PhD, professor, Department of Psychological and Brain Sciences, The University of Iowa, discusses a study investigating the effects of stress on immune response and tumor microenvironment in ovarian cancer and other cancer types.
Watch
Optimizing Neadjuvant Chemotherapy in Ovarian Cancer Depends on Patient Selection
November 11th 2016The use of neoadjuvant chemotherapy for the treatment of advanced ovarian cancer has risen dramatically in recent years, improving quality of life for patients and reducing morbidity, but challenges remain for oncologists looking to deploy this treatment approach in clinical practice.
Read More
Maintenance Olaparib Shown to Significantly Improve PFS in Ovarian Cancer Trial
October 27th 2016In a recent study, single-agent olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo in the maintenance setting for patients with advanced <em>BRAF</em>-positive ovarian cancer.
Read More
Findings of a Study With a Novel Antibody-Drug Conjugate in Ovarian Cancer
October 24th 2016Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a recent study of novel antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in ovarian cancer.
Watch
Jury Still Out on VEGF Inhibition Before Interval Debulking in Ovarian Cancer
October 19th 2016The rate of complete resection at interval debulking in advanced ovarian cancer increased significantly over reference values with the addition of bevacizumab (Avastin) to neoadjuvant to platinum-based chemotherapy.
Read More
Setback for Abiraterone Acetate in Recurrent Ovarian Cancer
October 12th 2016Although one patient with recurrent ovarian cancer achieved complete response, the first trial of abiraterone conducted in ovarian cancer was halted early due to low response, according to results from the CORAL phase 2 trial.
Read More
The Clinical Activity of Rucaparib in Patients With Ovarian Cancer
October 11th 2016Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the clinical activity and efficacy of rucaparib in patients with high-grade ovarian carcinoma and a BRCA mutation during an interview at the 2016 ESMO Congress.
Watch
Antibody-Drug Conjugate Achieves Encouraging Responses in Pretreated Ovarian Cancer
October 11th 2016Findings of a recent preliminary clinical trial showed one-fourth of patients with heavily pretreated advanced ovarian cancer achieved objective responses with novel antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7).
Read More
Rucaparib Produces High Response Rates in Heavily Pretreated Ovarian Cancer
October 11th 2016The majority of heavily pretreated patients with high-grade ovarian cancer (HGOV) and germline or somatic <em>BRCA</em> mutations showed a durable response to rucaparib, according to findings from an analysis of two phase II trials.
Read More
Niraparib is a Breakthrough for Patients With Ovarian Cancer, Expert Says
October 8th 2016Maintenance therapy with the PARP1/2 inhibitor niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline <em>BRCA</em>-positive platinum-sensitive, recurrent ovarian cancer, according to findings from the phase III NOVA trial.
Read More
When to Perform a Prophylactic Bilateral Oophorectomy in Ovarian Cancer
October 7th 2016Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses when to perform a prophylactic bilateral oophorectomy on a patient who does not have ovarian cancer, but has a known BRCA mutation.
Watch